A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Phase 3
300
about 6.6 years
12–17
15 sites in CA, DE, GA +6
About this study
Researchers are testing tirzepatide, a medication, to see how it affects weight and heart health in adolescents with obesity and related conditions. The trial will last about 76 weeks and may include up to 23 visits.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Tirzepatide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
tirzepatide
injection (Injection)
Primary: Percent Change from Baseline in Body Mass Index (BMI)
Secondary: Change from Baseline in Diastolic Blood Pressure (DBP), Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Peripheral Apnea-Hypopnea Index (pAHI), Change from Baseline in Systolic Blood Pressure (SBP), Change from Baseline in Waist Circumference, Percent Change from Baseline in Body Weight, Percent Change from Baseline in Total Body Fat Mass as Determined by Dual energy X-ray Absorptiometry (DXA), Percent Change from Baseline in Triglycerides
Endocrinology